Hematologic malignancies
Idp Discovery Pharma S.L. is active in clinical research for relapsed and refractory blood cancers, with studies involving multiple myeloma, B-cell lymphomas, and chronic lymphocytic leukemia. Its trial portfolio reflects a focus on malignancies of the lymphoid and plasma cell lineages.
- Multiple myeloma
- B-cell lymphoma
- Chronic lymphocytic leukemia
The sponsor’s hematology research includes both standalone and combination treatment settings across relapsed/refractory disease.
Small cell lung cancer
The company also funds clinical research in unresectable and metastatic small cell lung cancer, a highly aggressive thoracic malignancy. This area of interest includes treatment strategies for patients with advanced disease requiring systemic therapy.
- Unresectable small cell lung cancer
- Metastatic small cell lung cancer
- Thoracic oncology
Its oncology portfolio extends beyond hematology into solid-tumour research with emphasis on advanced-stage lung cancer.
Combination oncology regimens
Idp Discovery Pharma S.L. is involved in studies evaluating novel therapeutic combinations in oncology, including approaches that pair investigational treatment with chemotherapy. This reflects interest in both hematologic and lung cancer settings.
- Investigational combination therapy
- Chemotherapy-based regimens
- Advanced cancer treatment
These research areas align with clinical development in oncology across multiple disease contexts.
